The global inhaled nitric oxide market size was US$ 781.6 million in 2021. The global inhaled nitric oxide market size is forecast to reach US$ 1999.4 million by 2030, growing at a compound annual growth rate (CAGR) of 11% during the forecast period from 2022 to 2030.
Inhaling nitric oxide is possible through the nose or mouth. Relaxing the smooth muscles widens the blood vessels in the lungs. Using it together with a breathing machine (ventilator) and other agents can treat babies with pulmonary hypertension who have respiratory failure. It is clinically proven that nitric oxide dilates blood vessels and relieves muscle tension, enabling the body to absorb oxygen more efficiently. The use of nitric oxide generally involves the use of an oxygen machine (ventilator). Nitric oxide, when inhaled, is known to serve as an effective pulmonary vasodilator without causing the systemic vascular tone to decrease.
Factors Influencing Market Growth
Impact Analysis of COVID-19
The inhalation of nitric oxide exhibits antiviral properties and improves oxygenation; therefore, nitric oxide was tested as an experimental treatment for the COVID-19 virus. Additionally, it helped in protecting healthcare workers on the front lines of the pandemic. In addition, inhaled nitric oxide is being investigated for its potential role in supporting COVID-19 in pulmonary hypertension, ARDS, and other respiratory diseases, as well as undergoing several randomized clinical trials. Furthermore, Mallinckrodt has also initiated a retrospective study for the use of iNO in COVID-19 patients. Additionally, multiple clinical trials are underway for iNO as a treatment for COVID-19, and it has demonstrated promising results in the patient population.
Regional Insights
The Asia-Pacific region is forecast to experience rapid growth in the near future. Due to the highest live birth rate per 1000 people and the prevalence of respiratory distress syndrome, neonatal jaundice, and hypoxic respiratory failure due to persistent pulmonary hypertension of the newborn (PPHN). The competitive environment created by the emergence of local nitric oxide therapy system providers has contributed to the growth of the Asia-Pacific market.
Leading Competitors
The leading prominent companies profiled in the global inhaled nitric oxide market are:
Scope of the Report
The global inhaled nitric oxide market segmentation focuses on Application and Region.
Segmentation based on Application
Segmentation based on Region
[TABLE OF CONTENTS]
1 INTRODUCTION OF GLOBAL INHALED NITRIC OXIDE MARKET
1.1 OVERVIEW OF THE MARKET
1.2 SCOPE OF REPORT
1.3 ASSUMPTIONS
2 EXECUTIVE SUMMARY
3 RESEARCH METHODOLOGY
3.1 DATA MINING
3.2 VALIDATION
3.3 PRIMARY INTERVIEWS
3.4 LIST OF DATA SOURCES
4 GLOBAL INHALED NITRIC OXIDE MARKET OUTLOOK
4.1 OVERVIEW
4.2 MARKET DYNAMICS
4.2.1 DRIVERS
4.2.2 RESTRAINTS
4.2.3 OPPORTUNITIES
4.3 PORTERS FIVE FORCE MODEL
4.4 VALUE CHAIN ANALYSIS
5 GLOBAL INHALED NITRIC OXIDE MARKET, BY APPLICATION
5.1 OVERVIEW
5.2 NEONATAL RESPIRATORY TREATMENT
5.3 CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)
5.4 ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS)
5.5 OTHERS
6 GLOBAL INHALED NITRIC OXIDE MARKET, BY GEOGRAPHY
6.1 OVERVIEW
6.2 NORTH AMERICA
6.2.1 NORTH AMERICA MARKET SNAPSHOT
6.2.2 U.S.
6.2.3 CANADA
6.2.4 MEXICO
6.3 EUROPE
6.3.1 EUROPE MARKET SNAPSHOT
6.3.2 WESTERN EUROPE
6.3.2.1 THE UK
6.3.2.2 GERMANY
6.3.2.3 FRANCE
6.3.2.4 ITALY
6.3.2.5 SPAIN
6.3.2.6 REST OF WESTERN EUROPE
6.3.3 EASTERN EUROPE
6.3.3.1 POLAND
6.3.3.2 RUSSIA
6.3.3.3 REST OF EASTERN EUROPE
6.4 ASIA PACIFIC
6.4.1 ASIA PACIFIC MARKET SNAPSHOT
6.4.2 CHINA
6.4.3 JAPAN
6.4.4 INDIA
6.4.5 AUSTRALIA & NEW ZEALAND
6.4.6 ASEAN
6.4.7 REST OF ASIA PACIFIC
6.5 MIDDLE EAST & AFRICA
6.5.1 MIDDLE EAST & AFRICA MARKET SNAPSHOT
6.5.2 UAE
6.5.3 SAUDI ARABIA
6.5.4 SOUTH AFRICA
6.5.5 REST OF MEA
6.6 SOUTH AMERICA
6.6.1 SOUTH AMERICA MARKET SNAPSHOT
6.6.2 BRAZIL
6.6.3 ARGENTINA
6.6.4 REST OF SOUTH AMERICA
7 GLOBAL INHALED NITRIC OXIDE MARKET COMPETITIVE LANDSCAPE
7.1 OVERVIEW
7.2 COMPANY MARKET RANKING
7.3 KEY DEVELOPMENT STRATEGIES
8 COMPANY PROFILES
8.1 AIR LIQUIDE S.A.
8.1.1 OVERVIEW
8.1.2 FINANCIAL PERFORMANCE
8.1.3 PRODUCT OUTLOOK
8.1.4 KEY DEVELOPMENTS
8.2 BELLEROPHON THERAPEUTICS, INCORPORATED
8.2.1 OVERVIEW
8.2.2 FINANCIAL PERFORMANCE
8.2.3 PRODUCT OUTLOOK
8.2.4 KEY DEVELOPMENTS
8.3 BOC HEALTHCARE
8.3.1 OVERVIEW
8.3.2 FINANCIAL PERFORMANCE
8.3.3 PRODUCT OUTLOOK
8.3.4 KEY DEVELOPMENTS
8.4 BEYOND AIR, INCORPORATED
8.4.1 OVERVIEW
8.4.2 FINANCIAL PERFORMANCE
8.4.3 PRODUCT OUTLOOK
8.4.4 KEY DEVELOPMENTS
8.5 HALMA PLC
8.5.1 OVERVIEW
8.5.2 FINANCIAL PERFORMANCE
8.5.3 PRODUCT OUTLOOK
8.5.4 KEY DEVELOPMENTS
8.6 LINDE PLC
8.6.1 OVERVIEW
8.6.2 FINANCIAL PERFORMANCE
8.6.3 PRODUCT OUTLOOK
8.6.4 KEY DEVELOPMENTS
8.7 MALLINCKRODT PLC
8.7.1 OVERVIEW
8.7.2 FINANCIAL PERFORMANCE
8.7.3 PRODUCT OUTLOOK
8.7.4 KEY DEVELOPMENTS
8.8 NOVOTERIS, LLC
8.8.1 OVERVIEW
8.8.2 FINANCIAL PERFORMANCE
8.8.3 PRODUCT OUTLOOK
8.8.4 KEY DEVELOPMENTS
8.9 VERO BIOTECH LLC
8.9.1 OVERVIEW
8.9.2 FINANCIAL PERFORMANCE
8.9.3 PRODUCT OUTLOOK
8.9.4 KEY DEVELOPMENTS
8.10 NU-MED PLUS
8.10.1 OVERVIEW
8.10.2 FINANCIAL PERFORMANCE
8.10.3 PRODUCT OUTLOOK
8.10.4 KEY DEVELOPMENTS
01
お客様のニーズに合わせてレポートをカスタマイズ可能
02
ベテランの市場調査員による専門的な分析
03
安全で簡単に利用できるオンライン決済方法
04
お客様のご要望に応じて、特定の章を購入することができます。
05
すべてのレポートに専門的な日本語翻訳を提供
06
包括的でわかりやすいレポートを迅速にお届けします。
07
購入後も継続的なサポートとアップデートが受けられます。
We Accept
Copyright ©2022 All rights reserved